Early fertility screening has both potential benefits and risks: it can support informed life planning, but it also raises ethical questions and can trigger anxiety, guilt, or false reassurance if not handled carefully. The overall impact depends a lot on how tests are marketed, what is actually measured (for example AMH), and whether good counselling is provided before and after results.​

Key Ethical Issues

• Autonomy and informed consent: Ethically, adults should have the right to know about options like ovarian reserve or semen testing, but only with clear explanation of what the tests can and cannot predict. Direct‑to‑consumer AMH services are often criticised for overstating their ability to “predict” fertility or menopause timing, which can undermine truly informed consent.​
• Misleading claims and overmedicalisation: Major studies show AMH does not reliably predict natural fertility in otherwise healthy women, yet it is marketed as a “fertility score.” This can pathologise normal variation, turn healthy young people into “patients,” and divert attention from broader social issues like cost of living, childcare, or work policies that also shape reproductive choices.
  
• Justice and equity: Early screening is more accessible to urban, higher‑income groups, which may widen gaps in who gets timely information and options like egg freezing or IVF. There is also concern that commercial campaigns target women more than men, reinforcing gendered pressure and responsibility for fertility.​
  

Psychological Impacts of Results

• Distress with “low” reserve: Being told you have low AMH or poor ovarian reserve can trigger shock, grief, diminished self‑esteem, anxiety, and depressive symptoms, similar to reactions seen after infertility or premature ovarian insufficiency diagnoses. Some individuals feel rushed into partnerships, pregnancy, or expensive treatments, which can strain relationships and mental health.​
• False reassurance with “good” numbers: On the other hand, high or “normal” scores may create a false sense of security and encourage further delay of childbearing even though age remains the biggest factor for natural fertility. This can lead to disappointment later if conception is harder than expected, or if results are reinterpreted by another clinician.​
  

Ongoing Anxiety and Identity Issues

• Chronic worry and “fertility monitoring”: Some people begin repeatedly checking AMH or other markers, which can foster health anxiety and a sense that their reproductive future is constantly at risk. Stress and worry themselves may negatively affect ovarian function or IVF outcomes, creating a feedback loop between psychological distress and fertility.​
• Impact on self‑image and relationships: Fertility is often tied to ideas of femininity, masculinity, and adulthood, so abnormal results can damage body image or a sense of adequacy as a future parent. This can strain partner relationships, influence dating decisions, and, in some cases, lead to secrecy or shame around reproductive health.​
  

Mitigating Harms: Good Practice

• Pre‑ and post‑test counselling: Professional bodies emphasise that fertility investigations should be systematic and targeted, not routine “screening panels,” and that people need clear context about limitations and alternatives. Counselling can help translate results into realistic options (try sooner, lifestyle changes, preservation, or doing nothing yet) and provide emotional support where results are unexpected.​
• Responsible use and regulation: Ethically sound programmes avoid universal screening of low‑risk young people, limit tests to situations where results are actionable, and insist on honest, non‑alarmist messaging. Integrating mental‑health support and safeguarding against coercion (from partners, families, or employers) helps ensure early screening empowers rather than pressures individuals.